Quarry LP Buys 388 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Quarry LP increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 51.3% during the 2nd quarter, Holdings Channel reports. The fund owned 1,145 shares of the medical equipment provider’s stock after buying an additional 388 shares during the quarter. Quarry LP’s holdings in Lantheus were worth $92,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Farallon Capital Management LLC lifted its holdings in shares of Lantheus by 595.3% during the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock valued at $92,316,000 after purchasing an additional 1,269,900 shares in the last quarter. Swedbank AB bought a new position in Lantheus in the first quarter valued at approximately $26,346,000. Nomura Holdings Inc. boosted its holdings in shares of Lantheus by 105.3% in the fourth quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider’s stock valued at $1,282,000 after buying an additional 407,507 shares during the period. Westfield Capital Management Co. LP increased its position in shares of Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after acquiring an additional 394,837 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after acquiring an additional 389,828 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Activity at Lantheus

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Gary J. Pruden sold 12,530 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the transaction, the director now owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,852 shares of company stock worth $3,922,001. Corporate insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $105.18 on Thursday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company has a market cap of $7.29 billion, a PE ratio of 16.06 and a beta of 0.50. The business’s 50 day moving average price is $104.16 and its two-hundred day moving average price is $86.73. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter last year, the business earned $1.40 earnings per share. The company’s revenue was up 22.5% on a year-over-year basis. On average, analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on LNTH. B. Riley increased their target price on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Truist Financial decreased their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Leerink Partners increased their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Finally, JMP Securities lowered their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.